Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Businesses and Customers Benefit From New Partnerships
Posted on September 1st, 2017 by Prima Sung in Pharma R&D
Now more than ever, even some of the largest companies are seeking out partnerships, finding advantages in them for both businesses, while also providing greater value for customers and the industry as a whole. One such company is MilliporeSigma, a life science and biotech business owned by Merck KGaA, which is now expanding its reach with a couple of important collaborations. One involves opening up its distribution alliance with Public Health England further to include the European Bank for induced pluripotent Stem Cells, while the other is sharing its data with users of Elsevier’s chemistry database, Reaxys.
The partnership with Elsevier will integrate MilliporeSigma’s chemical products into Reaxys, giving users access to 43,000 of the company’s compounds and chemicals—and the ability to purchase them directly through an easy, time-saving process. MilliporeSigma initially came to Elsevier with the idea of partnering, and it was soon clear to both organizations that it would be a good match of “values, mission and customer focus,” according to Director of Chemistry Solutions at Elsevier, Christian Böhm. Both partners see this as a first step to what will likely include other forms of collaboration in the future.
Read this feature in DDNews to learn more about MilliporeSigma’s partnerships and the benefits that they anticipate will result from these relationships.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Sr. Product Marketing Manager at Elsevier
- Integrating Chemistry Data Sources Provides Big Benefits
- Beacon Discovery Leverages Partnerships and Elsevier Solutions to Further GCPR R&D Related Research
- Advances in Automated Chemistry Extraction from Patents
- Emulating start-up success with purpose-built data tools
- Small Biotechs Progressing Beyond Startup Status